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ABSTRACT Data on primary ciliary dyskinesia (PCD) epidemiology is scarce and published studies are
characterised by low numbers. In the framework of the European Union project BESTCILIA we aimed to
combine all available datasets in a retrospective international PCD cohort (iPCD Cohort).
We identified eligible datasets by performing a systematic review of published studies containing clinical
information on PCD, and by contacting members of past and current European Respiratory Society Task
Forces on PCD. We compared the contents of the datasets, clarified definitions and pooled them in a
standardised format.
As of April 2016 the iPCD Cohort includes data on 3013 patients from 18 countries. It includes data on
diagnostic evaluations, symptoms, lung function, growth and treatments. Longitudinal data are currently
available for 542 patients. The extent of clinical details per patient varies between centres. More than 50%
of patients have a definite PCD diagnosis based on recent guidelines. Children aged 10–19 years are the
largest age group, followed by younger children (⩽9 years) and young adults (20–29 years).
This is the largest observational PCD dataset available to date. It will allow us to answer pertinent
questions on clinical phenotype, disease severity, prognosis and effect of treatments, and to investigate
genotype–phenotype correlations.
This article has supplementary material available from erj.ersjournals.com
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Introduction
Primary ciliary dyskinesia (PCD) is a rare heterogeneous disease; genetic mutations cause functional and/
or structural defects of cilia [1, 2]. This results in chronic upper and lower respiratory disease, such as
progressive chronic suppurative lung disease, chronic serous otitis media (glue ear) and chronic
rhinosinusitis [3]. Nearly half of PCD patients have situs inversus [4] and some have other heterotaxic
syndromes or congenital heart defects [5, 6]. PCD affects about 1 in 10000 people [2, 7]. As in most
orphan diseases, research has focused on identifying the responsible genes, describing pathophysiological
mechanisms and improving diagnostic tests [8–11]. Clinical characteristics have been described mainly in
small case series and literature reviews. A recent meta-analysis found a wide range in reported prevalence
of clinical manifestations of PCD [12]. Earlier reports on PCD in children suggested a relatively benign
long-term course. This has been questioned by recent publications, which demonstrated that many adult
patients develop severe lung disease with chronic Pseudomonas infection, become oxygen dependent and
eventually require lung transplantation [3, 13–16]. Although growth and lung function are important
predictors of severity and prognosis in many lung diseases [17], data on PCD is scant, showing
contradictory results [13, 15, 18–23]. There are no age-standardised data on mortality and little is known
about factors influencing long-term prognosis. For instance, it is not clear how mortality and lung
function are influenced by different ultrastructural and genetic defects.
Although 7% of the population suffers from one of about 7000 rare diseases [24], research is scarce for these
disorders. Research on PCD and many other rare diseases cannot utilise routine data such as mortality and
hospital episode statistics because most rare diseases do not have a dedicated International Classification of
Diseases revision 10 code and can therefore not be identified in routine statistics. The low numbers of
patients in each individual centre call for collaborative research and international studies are essential.
Aware of these issues, clinicians and scientists with a strong interest in PCD formed an international focus
group in 2006 and took a number of initiatives to advance PCD research. The first Task Force on PCD
(2006–2009) of the European Respiratory Society (ERS) included 26 countries [1, 7, 25]. This European
network, under the framework of the European Union’s Seventh Framework Programme (EU FP7) project
BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia), joined forces
with the North American Genetic Disorders of Mucociliary clearance Consortium. Two work packages of
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BESTCILIA aimed to improve the availability of international datasets for PCD patients: 1) by setting up a
prospective international PCD registry [26], to allow standardised data collection in the future, and 2) by
identifying and combining available data on PCD in a retrospective international cohort study. This article
describes the aims and methods of the international PCD cohort (iPCD Cohort) and outlines how the
data can be accessed for future research.
Aims of the iPCD Cohort
The iPCD Cohort assembles available datasets with clinical and diagnostic data from PCD patients
worldwide to answer pertinent questions on clinical phenotype, disease severity, prognosis and effect of
treatments in patients with this rare multiorgan disease.
This combined international dataset allows investigation of PCD epidemiology in a large international
study population in order to: 1) describe the spectrum of clinical phenotypes and disease severity in PCD
patients by age, sex and time period of diagnosis; 2) describe short-term and long-term prognosis of PCD,
looking at important outcomes such as growth, lung function and respiratory failure, bacterial
colonisation, hearing loss, fertility, and mortality; and 3) identify predictors of long-term outcomes such as
age at diagnosis, clinical phenotype, ultrastructural defects, genotype and clinical care.
Methods
Study design
The iPCD Cohort is a retrospective international cohort, combining available data on PCD from national or
local registries and clinical or diagnostic databases. All participating centres delivered retrospectively collected
data; new centres joining the iPCD Cohort in the future can also participate with retrospectively collected data.
Identification of eligible datasets
Systematic literature search
In order to identify published data and eligible datasets we performed a systematic literature search for
studies describing clinical manifestations in patients with PCD [12]. We searched the online databases
PubMed, Embase and Scopus for studies published since 1980, without restrictions on language or study
design, including studies containing information on clinical manifestations of 10 or more PCD patients.
We also checked the reference lists of articles to find additional studies. We identified 52 different studies
and invited all corresponding authors to participate in the iPCD Cohort.
Other sources
Using the database set up in a previous European PCD survey [1, 5, 7] and personal contacts from the ERS
PCD Task Force, we contacted all clinicians who had reported treating PCD patients and asked them to
collaborate. This included physicians from Europe, North and South America, the Middle East, and Australia.
Data pooling and standardisation
Overall, diagnostic definitions have changed over the years. Cut-offs for diagnostic test results depend on
laboratory conditions, techniques and equipment used (e.g. the reference range for ciliary beat frequency is
dependent on the temperature at which analyses are made). Definitions of many clinical manifestations also
vary between countries and centres. We observed considerable heterogeneity in content and format between
the delivered datasets. For this reason, and to obtain comparable data for pooled analyses, we developed a
standardised dataset. We discussed the content and format of this dataset with all collaborators, who include
experts on PCD diagnostics and clinical care, and with PCD patient representatives, participating at
BESTCILIA meetings. For diagnostic tests results, in particular, we chose the use of categorical variables in
order to achieve standardisation and avoid misclassification at the time of analysis. Content and format of
the variables were tailored to the availability of retrospective data, as identified by examination of the
received datasets and the prospective international PCD registry [26]. This facilitates the close collaboration
between the two datasets for future research.
Diagnostic subgroups
PCD diagnostics have evolved rapidly in recent years [27]. Initially, diagnosis was based on the Kartagener
symptoms triad [28] and on transmission electron microscopy (TEM) findings. Then light microscopy and
later high-frequency video microscopy (VM) were introduced in the diagnostic algorithm. Currently,
recommendations include a combination of TEM, VM, nasal nitric oxide (nNO) and genetic testing [11], but
availability of tests differs between countries [27]. Therefore, not all PCD patients have been diagnosed
according to current recommendations. The iPCD Cohort includes patients diagnosed since 1964, when
diagnostic criteria were different. As a result of this, we defined three different diagnostic subgroups based on
the results of the available tests. We used the recent guidelines of the ERS PCD Diagnostics Task Force [11] to
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define “definite PCD” as hallmark TEM findings and/or bi-allelic PCD genetic mutation. “Probable PCD” was
defined when patients had abnormal VM findings and/or low nNO, using a cut-off of 77 nL·min−1, as
previously published [29]. All patients who had negative or ambiguous test results, or had not been tested so
far, were defined as having “clinical PCD diagnosis”. These patients are followed up and treated as PCD at the
collaborating centres based on a combination of several of the following features: situs anomalies, persistent
cough, persistent rhinitis, chronic or recurrent upper or lower respiratory infections and history of neonatal
respiratory symptoms in term infants, based on consensus statements and guidelines available to age [1, 11].
What information is collected
The iPCD Cohort includes retrospectively collected patient data on the following 11 thematic categories
(table 1): 1) general information, 2) results of diagnostic tests, 3) baseline characteristics, 4) growth and
lung function, 5) clinical manifestations, 6) therapy, 7) microbiology, 8) imaging, 9) surgical interventions,
10) neonatal period, and 11) family history. Details on all variables included in the standardised dataset
and information on the coding of variables are included in online supplementary table S1.
Infrastructure for data delivery and data rights
The iPCD Cohort is hosted at the Institute of Social and Preventive Medicine at the University of Bern,
Switzerland. Research is performed in close collaboration with all data contributors. We have set up a safe
information technology platform (Sharepoint) for uploading already available anonymised datasets. We
organised telephone conferences to offer extra support during the initial steps of the data delivery, and to
discuss questions and comments from the contributing partners. To further facilitate data delivery in the
standardised dataset for new partners we created a web-based platform, using the software Research
Electronic Data Capture (REDCap) developed at Vanderbilt University (Nashville, TN, USA), which is
TABLE 1 Description of data collected in the international primary ciliary dyskinesia cohort (iPCD Cohort) and centres
contributing to the different modules
Type of data Collected variables Contributing centres#
General information¶ Patient and centre identifiers, and demographic data (e.g. date of birth,
sex, ethnicity, date of last follow-up, date last known alive)
All centres
Diagnostics¶ Diagnostic status of PCD, date of diagnosis, dates, and results of
diagnostics test performed (e.g. nNO testing, VM, TEM, genetic testing)
All centres
Baseline characteristics¶ Information on PCD defects (e.g. situs anomalies, congenital heart
defects, brain cilia dysfunction, retinitis pigmentosa, renal problems,
fertility problems) and relevant comorbidities unconnected with PCD
All centres
Lung function Lung function date, somatometric measurement, spirometric
measurements and other lung function tests (e.g. multiple
breath washout)
All centres except
those in Northern America
Clinical manifestations Date of clinical visit, information on symptoms and signs (e.g. cough,
upper and lower respiratory infections, hearing impairment), exercise
limitation and active or passive smoking within the last 3 months
AR, AU, CH, CY, DE2, DE3, DK, FR, IL,
IT, NL, NO, PL, RS, TR, UK2, UK3
Therapy Date of prescription, information on inhaled and nasal medication (e.g.
bronchodilators, inhaled corticosteroids, nasal sprays), antibiotics
prescription, oxygen therapy, mechanical ventilation and physiotherapy
AU, CH, CY, DE3, IL, IT,
NO, PL, RS, TR, UK3
Microbiology Date of microbiology examination, type of sample and isolated bacteria AR, BE, CH, CY, DE2, DE3, DK,
NO, PL, RS, TR, UK2, UK3
Imaging Date of chest imaging examination, type of chest imaging, information
on findings (e.g. bronchiectases, atelectases, infiltrations) and
information on other types of imaging
BE, CH, CY, DE2, DE3, FR,
IL, IT, NO, RS, TR, UK2, UK3
Surgical interventions Date and type of surgery AR, AU, BE, CH, CY, DE3,
IT, NL, NO, RS, TR
Neonatal period Symptoms and signs of neonatal period (e.g. neonatal
respiratory distress syndrome, neonatal cough, neonatal
rhinitis), need for intensive care and ventilation
AU, BE, CH, CY, DE2, DE3,
FR, IL, IT, NL, NO, RS, TR, UK3
Family history Number of siblings, PCD affected siblings and other family
members, patient ID of PCD affected family members,
and relationship of affected family members
AR, AU, BE, CH, CY, DE2,
IL, IT, NO, RS, TR, UK3
nNO: nasal nitric oxide; VM: light or high-frequency video microscopy; TEM: transmission electron microscopy. #: AR: Argentina; AU: Australia;
BE: Belgium; CH: Switzerland; CY: Cyprus; DE1: Bochum, Germany, DE2: Muenster, Germany; DE3: Hannover, Germany; DK: Denmark;
FR: France; IL: Israel; IT: Italy; NL: the Netherlands; NO: Norway; PL: Poland; RS: Serbia; TR: Turkey; UK1: Paediatric Pulmonology Dept,
Brompton, UK; UK2: Adult Pulmonology Dept, Brompton, UK; UK3: Southampton, UK. ¶: mandatory data for all centres.
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widely used in the academic research community [30], and allows data entry and extraction in various
formats. Detailed instructions explain how data can be entered. The REDCap environment is completely
secure and each contributor only has access to the data of their own centre. We collaborated closely with
centres that already had national registries and large retrospective datasets, to help them recode the data
into the standardised format, and we performed quality controls of the delivered data (e.g. checks for
coding errors and plausibility of entered values and dates). Each partner was responsible for ensuring that
the delivered data were anonymous and in accordance with the national/local data protection laws. More
information on data protection can be found in the online supplementary material under Data protection/
Ethics. We drafted agreements for data delivery and publication (see online supplementary material),
which leave all rights with data contributors.
Data analysis
For each planned analysis, all eligible data are validated, cleaned and standardised. We identify outliers
and implausible values, and if necessary we contact contributors to resolve any issues encountered. Based
on the research question, we use a one- or two-stage random effect individual patient data meta-analysis
approach. As PCD diagnostics has evolved quickly and not all patients have diagnostic information that is
up to current standards, all analyses will be stratified by level of diagnostic certainty, using the diagnostic
subgroups described previously. Whenever relevant, we will perform additional sensitivity analysis
including only patients with definite PCD, based on the recent guidelines of the ERS PCD Diagnostics
Task Force [11], and will compare these results with the overall analysis results.
Funding
The setting up of the iPCD Cohort (salaries, consumables and equipment) was funded by the EU FP7
project BESTCILIA (http://bestcilia.eu) and several Swiss funding bodies, including the Lung Leagues of
Bern, St Gallen, Vaud, Ticino and Valais and the Milena Carvajal Pro-Kartagener Foundation. Data
collection and management at each site was funded according to local arrangements. Most participating
researchers and data contributors participate in the COST Action BEAT-PCD: Better Evidence to Advance
Therapeutic options for PCD (BM 1407; www.beatpcd.org). Infrastructure is provided for free by the
University of Bern, where the data are pooled and stored.
Results
Current dataset
The iPCD Cohort is an ongoing effort where new centres can still join and participating centres can add
data for new patients. As of April 2016, data from 21 single centres or consortia from 18 countries had been
Data richness:
Basic
Intermediate
Rich
FIGURE 1 Countries contributing data to the international primary ciliary dyskinesia cohort (iPCD Cohort). The
circle size reflects the size of the dataset and the shades of grey reflect the data richness (semiquantitative
measure based on the number of delivered variables).
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contributed. The pooled dataset contained data on 3013 patients (figure 1). Some countries which have a
national reference centre for all paediatric and adult PCD patients (Cyprus, Denmark and France) or a
national PCD registry (Italy and Switzerland) contributed their national dataset. Other countries
contributed data from their consortia of several centres (Israel, USA and Canada) or datasets from
single-centre studies (all remaining centres). The number of patients per centre ranged from 10 to 436
(table 2). Two paediatric centres contributed datasets only with patients <18 years and one with adult
patients (⩾20 years old). Five paediatric centres additionally included a few young adults. The remaining 13
centres submitted datasets that included both paediatric and adult patients with an age range from 0 to
77 years. The percentage of males ranged from 38% to 68% among datasets. General information, results of
diagnostic tests and baseline characteristics (Modules 1–3) are in the basic mandatory dataset, and thus
available from all centres and for all 3013 patients or the majority of them (tables 1 and 3). In addition to
these baseline data, several centres have also contributed data to the other modules (table 3). Data on
growth are currently available for more than 1500 patients and on lung function for more than 1000
patients. Additional data, such as microbiology or perinatal history, have been delivered by several groups
(table 1 and figure 1) and for several hundreds of patients (table 3). Longitudinal data have been
contributed for 542 patients from 10 countries (table 2), with a follow-up period ranging from 2 to 20 years.
Patient characteristics
Characteristics of the 3013 patients included in the iPCD Cohort are described in table 4. 49% (1490) were
male. 71% of patients were followed up in European centres (39% in Western Europe), 9% in Western Asia,
17% in America and 4% in Australia. More than half of the patients (table 4) have a definite PCD diagnosis
based the recent guidelines of the ERS PCD Diagnostics Task Force [11]. 14% of patients were defined as
probable PCD based on their diagnostic test results. In 30% of patients the test results were ambiguous or the
diagnostic algorithm had not been concluded and the diagnosis was based on clinical grounds based on
existing consensus or guidelines. Median (range) current age of patients was 18 (1–92) years (figure 2).
Children aged between 10 and 19 years were the largest age group (38%), followed by younger children
(0–9 years) and young adults (20–29 years) at 17% and 18%, respectively. The percentage of patients in the
remaining age groups had a declining trend from 10% for patients aged 30–39 years to 4% for patients
aged >60 years.
TABLE 2 Characteristics of the international primary ciliary dyskinesia cohort (iPCD Cohort)
Country Principal
investigator
Patients
n
Age range
years#
Males
%
Type of data
delivered
Data
richness¶
Argentina S. Scigliano 101 6–57 42 Cross-sectional Intermediate
Australia L. Morgan 109 0–76 60 Longitudinal High
Belgium M. Boon 82 0–69 45 Cross-sectional High
Cyprus P. Yiallouros 31 0–66 48 Longitudinal High
Denmark K.G. Nielsen 120 0–70 48 Longitudinal Intermediate
France A. Clement 337 0–69 52 Longitudinal High
Germany (Bochum) C. Koerner-Rettberg 64 0–27 40 Cross-sectional High
Germany (Muenster) H. Omran 436 3–75 52 Cross-sectional Basic
Germany (Hannover) N. Schwerk 37 0–39 68 Longitudinal High
Israel I. Amirav 210 0–60 56 Cross-sectional High
Italy Italian PCD group 331 0–73 50 Cross-sectional Intermediate
The Netherlands E. Haarman 82 3–69 50 Longitudinal Intermediate
Norway S. Crowley 23 0–18 65 Longitudinal High
Poland H. Mazurek 105 1–22 56 Cross-sectional High
Serbia Z. Zivkovic 10 6–19 45 Longitudinal High
Switzerland Swiss PCD group 108 3–70 51 Longitudinal High
Turkey B. Karadag 37 3–21 43 Cross-sectional Intermediate
UK (Paediatric Pulmonology Dept, Brompton) C. Hogg 116 1–18 47 Cross-sectional Basic
UK (Adult Pulmonology Dept, Brompton) M. Loebinger 152 20–76 38 Cross-sectional Basic
UK (Southampton) J. Lucas 104 0–68 49 Longitudinal Intermediate
USA/Canada Genetic Diseases of
Mucociliary Clearance
Consortium
418 0–77 44 Cross-sectional Basic
iPCD Cohort 3013 0–77 50
#: at time of data delivery; ¶: semiquantitative measure based on the number of delivered variables.
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Discussion
The iPCD Cohort is the largest PCD dataset available to date. It includes data from 3013 PCD patients
from 18 countries; more than half of them have a definite PCD diagnosis using current standards. The
main strength of the iPCD Cohort is the large number of patients it includes. This makes it a valuable
TABLE 3 Available data from different modules of the standardised dataset of 3013 primary
ciliary dyskinesia (PCD) patients in the international PCD cohort (iPCD Cohort) (April 2016)
Type of data Patients
General information 3013 (100)
Diagnostics 3013 (100)
nNO 1021 (33)
TEM 1913 (62)
VM 1088 (35)
Genetics 276 (9)
Baseline characteristics# 2286 (74)
Growth 1609 (53)
Lung function 1042 (34)
Clinical manifestations 1352 (44)
Therapy 843 (27)
Microbiology 732 (24)
Imaging 526 (17)
Neonatal period 1179 (38)
Data are presented as n (%). nNO: nasal nitric oxide; TEM: transmission electron microscopy; VM: light or
high-frequency video microscopy. #: mainly data on situs anomalies and congenital heart disease.
TABLE 4 Basic characteristics of the 3013 primary ciliary dyskinesia (PCD) patients included in
the international PCD cohort (iPCD Cohort) (April 2016)
Patients 3013 (100)
Sex
Male 1490 (49)
Female 1523 (51)
Location of country of residence#
Australia 109 (4)
Northern Europe 515 (17)
Western Europe 1146 (39)
Eastern Europe 105 (4)
Southern Europe 341 (11)
Western Asia 278 (9)
Northern America 418 (14)
Southern America 101 (3)
Diagnostic information
Definite PCD diagnosis¶ 1718 (56)
Probable PCD diagnosis+ 420 (14)
Clinical diagnosis only 875 (30)
Age years
0–9 517 (17)
10–19 1156 (38)
20–29 553 (18)
30–39 316 (10)
40–49 205 (7)
50–59 137 (5)
⩾60 129 (4)
Data are presented as n (%). #: based on geographical region definitions of the United Nations Statistic
Division (August 2016) (Northern Europe: Denmark, Norway, UK; Western Europe: Belgium, France,
Germany, Switzerland, the Netherlands; Eastern Europe: Poland; Southern Europe: Italy, Serbia; Western
Asia: Cyprus, Israel, Turkey; Northern America: Canada, USA; Southern America: Argentina); ¶: defined as
hallmark PCD electron microscopy findings and/or bi-allelic gene mutation identified based on the
European Respiratory Society PCD Diagnostics Task Force guidelines [11]; +: abnormal light or
high-frequency video microscopy finding and/or low (⩽77 nL·min−1) nasal nitric oxide value.
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source for research, especially in the field of rare diseases where even large national reference centres may
follow a small number of patients. In addition to the basic characteristics and diagnostic test results, which
are available from all centres and for more than 3000 patients, the iPCD Cohort includes data from over
1000 patients on neonatal symptoms, growth, lung function and clinical characteristics, and from several
hundred patients on other topics such as microbiology, imaging and therapy (e.g. growth, lung function,
clinical manifestations) from a number of centres; these are higher numbers of patients than were ever
previously included in publications on these topics. What is important is that most centres have included
almost complete datasets in the different thematic modules, in cases where they have contributed data to
them. Another strength is the multinational nature of the iPCD Cohort. It offers the possibility, unique for
rare diseases, to assess differences in PCD characteristics between countries and ethnic groups, and
variations in healthcare (diagnostics and treatment). The iPCD Cohort includes patients of all age groups
and although the paediatric population is larger, this offers the opportunity to study the course of the
disease through life. Preliminary analyses on growth, nutritional status and lung function from the iPCD
Cohort have been presented at international conferences, illustrating the quality of the dataset and the
feasibility of future studies using the iPCD Cohort. The user-friendly and safe environment of REDCap for
the standardised entry of the data is an additional strength. Data contributors can easily type in their data
following simple instructions and access it any time with password-protected accounts (box 1). In addition,
they can easily export their dataset for their own analyses.
Some limitations are inherent to the retrospective nature of the iPCD Cohort. For instance, there remains
some heterogeneity in definitions among centres. This is not an issue for standardised measurements, such
as height, weight, spirometry and microbiology/radiology test results, but is more relevant for clinical signs.
Reference ranges of diagnostic test results vary, and depend greatly on the expertise, conditions, equipment
and protocol used at each centre. For standardisation with comparable values, we used categorical coding for
numerical values (e.g. frequency of ciliary beating has been coded as normal/decreased/increased). All the
items collected in the cohort and their coding were extensively discussed and agreed among collaborators
during the development period, taking into account existing national registries and the prospective
international PCD registry. This ensures that all important data resources could be pooled and analysed
together in future collaborative studies. Another issue is the heterogeneity of the PCD patient population
concerning the diagnostic evaluation; diagnostic results can be normal or very subtle in some patients who
almost certainly have PCD. Therefore, we have grouped the patients into three subgroups based on the
recent diagnostics guidelines from the ERS Task Force [11] and are planning to take the level of diagnostic
certainty into account in all analyses. Participating centres will be encouraged to follow these guidelines for
new patients and to re-evaluate the diagnosis of patients in cases where not all testing has been concluded.
Although the iPCD Cohort is an important data source for statistically meaningful research, it is not truly
representative of the PCD patient population. Countries that have not developed diagnostic facilities yet are
under-represented. PCD is underdiagnosed in adults, and most centres follow mainly children and younger
adults. Thus, adult patients, especially those of older age, are under-represented in the Cohort.
Most published studies on PCD include a small number of patients. The largest published study on PCD
was in the framework of the previous ERS PCD Task Force, which included 1192 patients from 26
countries [7]. In that study the researchers collected basic data from questionnaires addressed to the clinical
centres of participating countries. They found a slightly higher proportion of male patients and 85% of the
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FIGURE 2 Age distribution of 3013 primary ciliary dyskinesia (PCD) patients included in the international PCD cohort (iPCD Cohort), stratified by
sex: a) male and b) female (April 2016).
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patients were aged <20 years. Recently, data on 201 patients from the international PCD registry have been
described [26]. The authors observed 55% males and almost 50% patients aged <18 years. 22% of the
included patients have only a clinical diagnosis compared with 35% in the iPCD Cohort. As these two
datasets were both built in the framework of BESTCILIA there is an overlap in the patients they include.
The international PCD registry aims to collect prospective data of PCD patients in a standardised way to
use for future studies, while the iPCD Cohort combines available retrospective datasets of PCD patients in
pooled analyses to answer important questions on PCD in a large study population. Although well-designed
prospective studies have obvious strengths, it is of great importance to use all available data resources for
research in rare diseases such as PCD, where there is still little evidence and management of patients is
primarily based on experience derived from other diseases, such as cystic fibrosis.
The iPCD Cohort is a valuable resource for epidemiological studies in PCD and it can be further enriched
and used in the framework of the BEAT-PCD EU COST Action. BEAT-PCD aims to set up a global,
Europe-led multidisciplinary network of PCD clinicians and researchers, and the aims of the
epidemiological work group include using this dataset for projects on PCD epidemiology. More centres
have expressed an interest in contributing data to the cohort. Some groups had originally contributed a
basic cross-sectional dataset and are now adding retrospectively collected repeated measurements
(longitudinal data) or they are adding new patients to their datasets. Ongoing studies analyse growth, lung
function, diagnostic tests, clinical manifestations, neonatal symptoms and the role of lobectomy in PCD,
using the iPCD Cohort dataset. The iPCD Cohort also contains data on treatments, imaging and
microbiology, which can be used and to identify patients for nested studies on PCD.
This dataset is now available to be further exploited and offers a unique opportunity to study PCD in a
large international patient-based cohort with sufficient statistical power. Results will help to improve
survival, care and quality of life of PCD patients.
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BOX 1 Contributing to and accessing data in the international primary ciliary dyskinesia
cohort (iPCD Cohort)
How to contribute data
Centres that wish to participate to the project and contribute data can contact the iPCD Cohort to sign a
data delivery agreement. They then will receive a password to access the online software REDCap and
they will be able to enter their data directly. They can also upload follow-up data or add additional
patients at a later time point. In case of large standardised datasets, it is possible to upload them
directly. We have developed detailed instructions and offer information technology support wherever
needed
How to access data
Centres that have entered their data using REDCap will keep constant access to their datasets and can
export them directly in various formats for local analyses. We have developed detailed extraction
instructions to simplify the procedure.
Researchers wanting to use the iPCD Cohort dataset can propose a topic and a concept sheet describing
the planned analyses and publication. All concept sheets have to be approved by all centres
contributing data to the proposed analysis under question. After the participating centres agree to
contribute their data and sign a publication agreement, we will prepare a partial dataset for the
proposed analysis and will work closely with the lead researchers offering methodological input and
support. In case additional data is collected to complete the partial dataset for a specific project, this
will be added to the iPCD Cohort to enrich it after each project.
For further details, contact: pcd@ispm.unibe.ch
REDCap: Research Electronic Data Capture.
https://doi.org/10.1183/13993003.01181-2016 9
PRIMARY CILIARY DYSKINESIA | M. GOUTAKI ET AL.
References
1 Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and
treatment approaches in children. Eur Respir J 2009; 34: 1264–1276.
2 Lucas JS, Walker WT, Kuehni CE, et al. Primary ciliary dyskinesia. In: Courdier J-F, ed. Orphan Lung Diseases
(ERS Monograph). Sheffield, European Respiratory Society, 2011; pp. 201–217.
3 Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J
Respir Crit Care Med 2004; 169: 459–467.
4 Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007; 92:
1136–1140.
5 Shapiro AJ, Davis SD, Ferkol T, et al. Laterality defects other than situs inversus totalis in primary ciliary
dyskinesia: insights into situs ambiguus and heterotaxy. Chest 2014; 146: 1176–1186.
6 Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects in a large cohort
of patients with primary ciliary dyskinesia. Circulation 2007; 115: 2814–2821.
7 Kuehni CE, Frischer T, Strippoli MP, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in
European children. Eur Respir J 2010; 36: 1248–1258.
8 Jackson CL, Behan L, Collins SA, et al. Accuracy of diagnostic testing in primary ciliary dyskinesia. Eur Respir J
2016; 47: 837–848.
9 Kurkowiak M, Zietkiewicz E, Witt M. Recent advances in primary ciliary dyskinesia genetics. J Med Genet 2015; 52: 1–9.
10 Werner C, Onnebrink JG, Omran H. Diagnosis and management of primary ciliary dyskinesia. Cilia 2015; 4: 2.
11 Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary
dyskinesia. Eur Respir J 2017; 49: 1601090.
12 Goutaki M, Meier B, Halbeisen F, et al. Clinical manifestations in primary ciliary dyskinesia: systematic review and
meta-analysis. Eur Respir J 2016; 48: 1081–1095.
13 Marthin JK, Petersen N, Skovgaard LT, et al. Lung function in patients with primary ciliary dyskinesia:
a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010; 181: 1262–1268.
14 Alanin MC, Nielsen KG, von Buchwald C, et al. A longitudinal study of lung bacterial pathogens in patients with
primary ciliary dyskinesia. Clin Microbiol Infect 2015; 21: 1093.
15 Maglione M, Bush A, Nielsen KG, et al. Multicenter analysis of body mass index, lung function, and sputum
microbiology in primary ciliary dyskinesia. Pediatr Pulmonol 2014; 49: 1243–1250.
16 Shah A, Shoemark A, MacNeill S, et al. A longitudinal study characterising a large adult primary ciliary dyskinesia
population. Eur Respir J 2016; 48: 441–450.
17 Miller MR, Pedersen OF, Lange P, et al. Improved survival prediction from lung function data in a large
population sample. Respir Med 2009; 103: 442–448.
18 Cohen-Cymberknoh M, Simanovsky N, Hiller N, et al. Differences in disease expression between primary ciliary
dyskinesia and cystic fibrosis with and without pancreatic insufficiency. Chest 2014; 145: 738–744.
19 Svobodova T, Djakow J, Zemkova D, et al. Impaired growth during childhood in patients with primary ciliary
dyskinesia. Int J Endocrinol 2013; 2013: 731423.
20 Boon M, Smits A, Cuppens H, et al. Primary ciliary dyskinesia: critical evaluation of clinical symptoms and
diagnosis in patients with normal and abnormal ultrastructure. Orphanet J Rare Dis 2014; 9: 11.
21 Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J
1997; 10: 2376–2379.
22 Magnin ML, Cros P, Beydon N, et al. Longitudinal lung function and structural changes in children with primary
ciliary dyskinesia. Pediatr Pulmonol 2012; 47: 816–825.
23 Davis SD, Ferkol TW, Rosenfeld M, et al. Clinical features of childhood primary ciliary dyskinesia by genotype
and ultrastructural phenotype. Am J Respir Crit Care Med 2015; 191: 316–324.
24 Orphanet. 2015 Activity Report. www.orpha.net/orphacom/cahiers/docs/GB/ActivityReport2015.pdf Date last acce-
ssed: August 1, 2016.
25 Strippoli MP, Frischer T, Barbato A, et al. Management of primary ciliary dyskinesia in European children:
recommendations and clinical practice. Eur Respir J 2012; 39: 1482–1491.
26 Werner C, Lablans M, Ataian M, et al. An international registry for primary ciliary dyskinesia. Eur Respir J 2016;
47: 849–859.
27 Lucas JS, Paff T, Goggin P, et al. Diagnostic methods in primary ciliary dyskinesia. Paediatr Respir Rev 2016; 18: 8–17.
28 Kartagener M. Zur pathogenese der bronkiectasien: bronkiectasien bei situs viscerum inversus. Beitr Klin Tuberk
1933; 82: 489–501.
29 Lindberg S, Cervin A, Runer T. Low levels of nasal nitric oxide (NO) correlate to impaired mucociliary function
in the upper airways. Acta Otolaryngol 1997; 117: 728–734.
30 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology
and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
https://doi.org/10.1183/13993003.01181-2016 10
PRIMARY CILIARY DYSKINESIA | M. GOUTAKI ET AL.
